临床医学工程
臨床醫學工程
림상의학공정
Clinical Medical & Engineering
2015年
11期
1543-1544
,共2页
洋葱伯克霍尔德菌%临床分布%耐药性变迁
洋蔥伯剋霍爾德菌%臨床分佈%耐藥性變遷
양총백극곽이덕균%림상분포%내약성변천
Burkholeder cepacia%Clinical distribution%Drug resistance vicissitude
目的 分析220例洋葱伯克霍尔德菌临床分离株的分布特点及耐药性变迁情况, 为临床有效用药及院感防控提供依据. 方法 回顾性统计分析用MicroScan Wa1k Away 96全自动细菌分析系统培养、 鉴定出的洋葱伯克霍尔德菌的分布及药敏试验情况. 结果 共分离出220株洋葱伯克霍尔德菌, 年检出比率相对稳定在0.5%左右. 分离自痰液标本最多, 占80%, 其次为分泌物. 来自器官移植病区比例最高, 占41%; 其次为ICU病区. 洋葱伯克霍尔德菌对适用的主要抗生素甲氧苄啶/磺胺甲噁唑(SXT)、 左旋氧氟沙星 (LVX)、 头孢他啶 (CAZ)、 替卡西林/克拉维酸钾 (TIM) 的耐药率分别为10%、 14%、 30%、 76%. 结论 洋葱伯克霍尔德菌对适用药物仍较敏感, 但主要适用药物的耐药率以阶梯状上升; 甲氧苄啶/磺胺甲噁唑依然是治疗该菌的首选药物. 该菌在不同地区对同一种药物的耐药率差异明显, 不同医院患者感染该菌存在明显差异, 临床用药及医院感染防控时应根据地域与本院特点选择合适药物与防控.
目的 分析220例洋蔥伯剋霍爾德菌臨床分離株的分佈特點及耐藥性變遷情況, 為臨床有效用藥及院感防控提供依據. 方法 迴顧性統計分析用MicroScan Wa1k Away 96全自動細菌分析繫統培養、 鑒定齣的洋蔥伯剋霍爾德菌的分佈及藥敏試驗情況. 結果 共分離齣220株洋蔥伯剋霍爾德菌, 年檢齣比率相對穩定在0.5%左右. 分離自痰液標本最多, 佔80%, 其次為分泌物. 來自器官移植病區比例最高, 佔41%; 其次為ICU病區. 洋蔥伯剋霍爾德菌對適用的主要抗生素甲氧芐啶/磺胺甲噁唑(SXT)、 左鏇氧氟沙星 (LVX)、 頭孢他啶 (CAZ)、 替卡西林/剋拉維痠鉀 (TIM) 的耐藥率分彆為10%、 14%、 30%、 76%. 結論 洋蔥伯剋霍爾德菌對適用藥物仍較敏感, 但主要適用藥物的耐藥率以階梯狀上升; 甲氧芐啶/磺胺甲噁唑依然是治療該菌的首選藥物. 該菌在不同地區對同一種藥物的耐藥率差異明顯, 不同醫院患者感染該菌存在明顯差異, 臨床用藥及醫院感染防控時應根據地域與本院特點選擇閤適藥物與防控.
목적 분석220례양총백극곽이덕균림상분리주적분포특점급내약성변천정황, 위림상유효용약급원감방공제공의거. 방법 회고성통계분석용MicroScan Wa1k Away 96전자동세균분석계통배양、 감정출적양총백극곽이덕균적분포급약민시험정황. 결과 공분리출220주양총백극곽이덕균, 년검출비솔상대은정재0.5%좌우. 분리자담액표본최다, 점80%, 기차위분비물. 래자기관이식병구비례최고, 점41%; 기차위ICU병구. 양총백극곽이덕균대괄용적주요항생소갑양변정/광알갑오서(SXT)、 좌선양불사성 (LVX)、 두포타정 (CAZ)、 체잡서림/극랍유산갑 (TIM) 적내약솔분별위10%、 14%、 30%、 76%. 결론 양총백극곽이덕균대괄용약물잉교민감, 단주요괄용약물적내약솔이계제상상승; 갑양변정/광알갑오서의연시치료해균적수선약물. 해균재불동지구대동일충약물적내약솔차이명현, 불동의원환자감염해균존재명현차이, 림상용약급의원감염방공시응근거지역여본원특점선택합괄약물여방공.
Objective To investigate the clinical specimens distribution and drug resistance vicissitudes of 220 Burkholderia cepacia strains, so as to provide effective medication for clinic and evidence to hospital infection control. Methods We retrospectively analyzed the distribution and antimicrobial susceptibility of Burkholderia cepacia isolated by MicroScan Walk Away 96 full automated microblology analyzer. Results A total of 220 strains of Burkholeder cepacia were isolated. The positive rate of this bacterium stabled at 5%. The isolates were most from sputum samples, accounted for 80%, followed by the secretion. The positive isolates were most from organ transplantation ward and accounted for 41%, followed by ICU. The antibiotic resistant rates of Burkholeder cepacia to trimethoprim/sulfamethox azole (SXT), levofloxacin (LVX), ceftazidime (CAZ), ticarcillin/clavulanate potassium (TIM) were 10%, 14%, 30%, 76%, respectively. Conclusions Burkholeder cepacia is still sensitive to applicable medicine. But the resistant rates of the main medicine are increased by echelonment. Trimethoprim/sulfamethoxazole is still the first choice to treat this germ. The resistant rates of this germ to the same medicine are significant difference in different districts. Significant difference is found in infection patients of different hospitals. Clinical medication and hospital infection control should chose suitable medicine to control.
